Itraconazole is a first-generation triazole agent with an extended spectrum of activity; it is licensed in adults for superficial and systemic fungal infections; no recommendation has been yet established for use in children patients. Its variable and unpredictable oral bioavailability make it difficult to determine the optimal dosing regimen. Hence, therapeutic drug monitoring, highly available in clinical practice, may improve itraconazole treatment success and safety. The aim of the study was to describe in paediatrics the oral itraconazole pharmacokinetics, used for prophylaxis. Moreover, we evaluated the utility of its therapeutic drug monitoring in this cohort. A fully validated chromatographic method was used to quantify itraconazole concentration in plasma collected from paediatric patients, at the end of dosing interval. Associations between variables were tested using the Pearson test. Mann-Whitney U test has been used to probe the influence of categorical variables on continuous ones. Any predictive power of the considered variables was finally evaluated through univariate and multivariate linear and logistic regression analyses. A high inter-individual variability was shown; ethnicity (beta coefficient, β: -0.161 and interval of confidence at 95%, IC: -395.035;-62.383) and gender (β: 0.123 and IC: 9.590; 349.395) remained in the final linear regression model with p value of 0.007 and 0.038, respectively. This study highlights that therapeutic drug monitoring is required to achieved an adequate target itraconazole serum exposure. This article is protected by copyright. All rights reserved.

Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children

ALLEGRA, SARAH
First
;
FATIGUSO, GIOVANNA;DE FRANCIA, SILVIA;FAVATA, FABIO;PIRRO, Elisa;CARCIERI, CHIARA;DE NICOLO', AMEDEO;CUSATO, JESSICA;DI PERRI, Giovanni;D'AVOLIO, ANTONIO
Last
2017

Abstract

Itraconazole is a first-generation triazole agent with an extended spectrum of activity; it is licensed in adults for superficial and systemic fungal infections; no recommendation has been yet established for use in children patients. Its variable and unpredictable oral bioavailability make it difficult to determine the optimal dosing regimen. Hence, therapeutic drug monitoring, highly available in clinical practice, may improve itraconazole treatment success and safety. The aim of the study was to describe in paediatrics the oral itraconazole pharmacokinetics, used for prophylaxis. Moreover, we evaluated the utility of its therapeutic drug monitoring in this cohort. A fully validated chromatographic method was used to quantify itraconazole concentration in plasma collected from paediatric patients, at the end of dosing interval. Associations between variables were tested using the Pearson test. Mann-Whitney U test has been used to probe the influence of categorical variables on continuous ones. Any predictive power of the considered variables was finally evaluated through univariate and multivariate linear and logistic regression analyses. A high inter-individual variability was shown; ethnicity (beta coefficient, β: -0.161 and interval of confidence at 95%, IC: -395.035;-62.383) and gender (β: 0.123 and IC: 9.590; 349.395) remained in the final linear regression model with p value of 0.007 and 0.038, respectively. This study highlights that therapeutic drug monitoring is required to achieved an adequate target itraconazole serum exposure. This article is protected by copyright. All rights reserved.
44
11
1083
1088
HPLC; antifungal; invasive fungal infections; itraconazole; paediatrics; therapeutic drug monitoring
Allegra, Sarah; Fatiguso, Giovanna; De Francia, Silvia; Favata, Fabio; Pirro, Elisa; Carcieri, Chiara; De Nicolò, Amedeo; Cusato, Jessica; Di Perri, Giovanni; D'Avolio, Antonio
File in questo prodotto:
File Dimensione Formato  
Allegra_et_al-2017-Clinical_and_Experimental_Pharmacology_and_Physiology.pdf

Accesso aperto

Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 679.03 kB
Formato Adobe PDF
679.03 kB Adobe PDF Visualizza/Apri
Allegra_et_al-2017-Clinical_and_Experimental_Pharmacology_and_Physiology (1).pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 376.48 kB
Formato Adobe PDF
376.48 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1650598
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 11
social impact